Show simple item record

AuthorYounis, Nour K
AuthorYassine, Hadi M
AuthorEid, Ali H
Available date2023-01-29T06:52:25Z
Publication Date2022-12-28
Publication NameCurrent Medicinal Chemistry
Identifierhttp://dx.doi.org/10.2174/0929867330666221228121947
CitationYounis K Nour, Yassine M. Hadi and Eid H Ali*, Nanomedicine for Cancer, Current Medicinal Chemistry 2023; 30() . https://dx.doi.org/10.2174/0929867330666221228121947
ISSN0929-8673
URIhttp://hdl.handle.net/10576/38997
AbstractOver the past decades, oncology has occupied the lion’s share of all nanomedical applications [1-3]. In 2020, up to 65% of the clinical trials involving nanomaterials were attending to cancer therapeutics and diagnostics [4]. The focus of most trials is not limited to enhancing the efficacy of available therapeutics or the accuracy and precision of existing diagnostic tools but rather directed to improving the quality of life of cancer patients. Indeed, one approach to overcoming drug resistance can be achieved via modulating the pharmacological characteristics of these therapies [4, 5]. This, in turn, permits their passive and selective delivery to the targeted tumorigenic sites. Furthermore, the use of biocompatible drug delivery systems embracing cancer-specific antibodies facilitates the active delivery of these therapeutics to cancer cells [6].
Languageen
PublisherBentham Science Publishers
SubjectNanomedicine
Cancer
TitleNanomedicine for Cancer.
TypeOther
Volume Number30
ESSN1875-533X
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record